8-K - Kairos Pharma, LTD. (0001962011) (Filer)
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Kairos Pharma filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- KAPA Kairos Pharma-53.6% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- PFE Pfizer+9.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- MRK Merck+3.3% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| KAPA | +2.81% | +6.18% | base | -13.76% | after close | after close | after close |
| XLV | -2.95% | -0.31% | base | +0.32% | after close | after close | after close |
| XBI | +1.84% | +3.78% | base | +2.53% | after close | after close | after close |
| LLY | -9.22% | -2.71% | base | +0.47% | after close | after close | after close |
| JNJ | -0.68% | +1.70% | base | -0.36% | after close | after close | after close |
| PFE | -3.00% | -2.47% | base | -0.99% | after close | after close | after close |
| MRK | -4.45% | -1.43% | base | -2.28% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001493152-26-049744 Size: 10 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
The price since 3 Nov 2026: Kairos Pharma (KAPA) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | -0.36% | still updating |
| Johnson & Johnson (JNJ) | three days earlier | +1.70% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.68% | final price |
| Kairos Pharma (KAPA) | that day | -13.76% | still updating |
| Kairos Pharma (KAPA) | three days earlier | +6.18% | final price |
| Kairos Pharma (KAPA) | five days earlier | +2.81% | final price |
| Eli Lilly (LLY) | that day | +0.47% | still updating |
| Eli Lilly (LLY) | three days earlier | -2.71% | final price |
| Eli Lilly (LLY) | five days earlier | -9.22% | final price |
| Merck (MRK) | that day | -2.28% | still updating |
| Merck (MRK) | three days earlier | -1.43% | final price |
| Merck (MRK) | five days earlier | -4.45% | final price |
| Pfizer (PFE) | that day | -0.99% | still updating |
| Pfizer (PFE) | three days earlier | -2.47% | final price |
| Pfizer (PFE) | five days earlier | -3.00% | final price |
| Spdr Series Trust (XBI) | that day | +2.53% | still updating |
| Spdr Series Trust (XBI) | three days earlier | +3.78% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.84% | final price |
| Select Sector Spdr Tr (XLV) | that day | +0.32% | still updating |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.31% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Kairos Pharma (KAPA)
Companies tied to this story
- KAPA Kairos Pharma
Kairos Pharma (KAPA) is linked, with no stored direction, high confidence in the 3 Nov 2026 story “8-K - Kairos Pharma, LTD. (0001962011) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> KAPA
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - Kairos Pharma, LTD. (0001962011) (Filer).” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
- XBI Spdr Series Trust
For “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
- LLY Eli Lilly
In “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- JNJ Johnson & Johnson
In “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- PFE Pfizer
For “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- MRK Merck
In “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
How “8-K - Kairos Pharma, LTD. (0001962011) (Filer)” reaches Kairos Pharma (KAPA)
Kairos Pharma (KAPA) is the company in “8-K - Kairos Pharma, LTD. (0001962011) (Filer),” the 3 Nov 2026 this story story.
Kairos Pharma (KAPA) is on the page because SEC 8-K filing -> direct issuer disclosure -> KAPA
Also listed, Select Sector Spdr Tr (XLV): Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
The price range for Kairos Pharma (KAPA), and the dates in the story
KAPA traded between 0.52 and 2.15 across 20 sessions. The latest close on file is 0.52.
What the saved facts support for Kairos Pharma (KAPA)
46 out of 100Price not final
“8-K - Kairos Pharma, LTD. (0001962011) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies. The price is not final yet.